CYTK as reported
Cytokinetics, Incorporated reported $68M of revenue over the trailing twelve months, −21% on the year before. 9 reported series are charted on this page, each one as filed.
$68M
Revenue, trailing twelve months · to Q2 2026 · −21% against the twelve months before
- Net Income
- −$894M
Net Income · +47% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$581M
Free Cash Flow · +32% year on year · trailing twelve months to Q2 2026
- Op Margin
- −2798%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $68M | −21% | Q2 2026 |
| Net Income | −$894M | +47% | Q2 2026 |
| EPS | −$7.22 | +42% | Q2 2026 |
| Op Margin | −2798% | n/a | Q2 2026 |
| Net Margin | −4651% | n/a | Q2 2026 |
| ROE | 220% | n/a | Q2 2026 |
| ROA | −55% | n/a | Q2 2026 |
| ROIC | 41% | n/a | Q2 2026 |
| Free Cash Flow | −$581M | +32% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Cytokinetics, Incorporated (CYTK) - Revenue & ProfitRevenue & ProfitCytokinetics, Incorporated (CYTK)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com